Navigation Links
GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

ATLANTA, Feb. 25, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2010.

GeoVax reported a net loss of $478,784 for the fourth quarter ended December 31, 2010, as compared to a net loss of $843,275 for the comparable period in 2009. For the full year of 2010, the Company reported a net loss of $2,747,328 as compared to a net loss of $3,284,252 in 2009.  Grant revenues were $5,185,257 and $3,668,195 for the years ended December 31, 2010 and 2009, respectively.  As of December 31, 2010, the Company reported cash balances totaling $1,079,087.  Summarized financial information is attached.  Further information concerning the Company's financial position and results of operations are included in its Annual Report on Form 10-K, expected to be filed with the Securities and Exchange Commission before March 31, 2011.

Highlights of the Company's scientific and clinical progress during 2010 are as follows:

  • Early results from the Phase 2a trial for the preventative version of GeoVax's vaccine indicated an excellent safety profile and highly reproducible immunogenicity.  This trial was expanded to include testing of an additional, simpler vaccine regimen, and we expect patient enrollment and vaccinations to be completed during 2011.

  • During 2010, GeoVax began recruiting and screening patients for a Phase 1/2 trial for the therapeutic version of our vaccine.  In order to accelerate enrollment in this important study, a second site at the University of Alabama, Birmingham was recently added to complement the enrollment already underway in Atlanta.

  • We reported preclinical results using GM-CSF (granulocyte/macrophage
    '/>"/>

  • SOURCE GeoVax Labs, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
    2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
    3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
    5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
    6. GeoVax to Present at the BIO CEO & Investor Conference 2009
    7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
    8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
    9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
    10. GeoVax Labs, Inc. Announces First Quarter Financial Results
    11. GeoVax to Exhibit at the 2009 BIO International Convention
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
    (Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
    (Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
    (Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
    Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
    ... MINNEAPOLIS, Aug. 24, 2011 Cellectis bioresearch, the ... Cellectis (Alternext: ALCLS), and Recombinetics, a specialist in ... development and license agreement on the creation of ... accordance with biosafety and animal well-being requirements, large ...
    ... Pa., Aug. 24, 2011 Kibow Biotech, Inc. today ... and marketing agreement with the current licensing partner specializing ... 100% natural, probiotic dietary supplement indicated for the reduction ... severe renal failure. Developed by Kibow, Azodyl™ has been ...
    ... SPRING, Md., Aug. 24, 2011 United Therapeutics ... the completion of its FREEDOM-C(2) Phase 3 trial ... release oral formulation of treprostinil, a stable synthetic ... hypertension (PAH).  Preliminary analysis demonstrates that the trial ...
    Cached Biology Technology:Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4
    (Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
    (Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
    Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... “cautionary tale?about what may go wrong when using the fledgling ... , In the February 16 issue of the Journal of ... M. D. Anderson Cancer Center detail why an experimental test ... of blood is unlikely to lead to a reliable clinical ...
    ... what may go wrong when using the fledgling science of ... the February 16 issue of the Journal of the National ... Anderson Cancer Center detail why an experimental test intended to ... is unlikely to lead to a reliable clinical test right ...
    ... of,HIV infection per act of heterosexual sex among a ... have more,than twice the risk of acquiring HIV than ... 15 issue of The Journal of,Infectious Diseases, now available ... Kenya collected detailed sexual data from a,group of male ...
    Cached Biology News:Signaling protein builds bigger, better bones in mice 2Signaling protein builds bigger, better bones in mice 3New species from old data 2New species from old data 3Male circumcision reduces risk of HIV transmission from women to men 2
    Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
    ... Note: Assays in Tris buffer, pH 10.2 ... glycine buffer system. Assays in diethanolamine buffer, ... of the glycine buffer system. Protein determined ... Tris-citrate buffer salts Preparation Unit Definition: One ...
    ... a wide variety of solvent vapors that can contaminate ... (GCF400) allows for the collection of liquid into a ... minimizes waiting period., Ultra low -104 o ... , Digital Display of temperature ...
    ... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
    Biology Products: